Market capitalization | $1.05b |
Enterprise Value | $704.49m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 398.02 |
P/S ratio (TTM) P/S ratio | 595.72 |
P/B ratio (TTM) P/B ratio | 2.52 |
Revenue growth (TTM) Revenue growth | 20.97% |
Revenue (TTM) Revenue | $1.77m |
As a Free StocksGuide user, you can view scores for all 6,908 stocks worldwide.
10 Analysts have issued a Praxis Precision Medicines Inc forecast:
10 Analysts have issued a Praxis Precision Medicines Inc forecast:
Jun '24 | |
Current assets | 357 357 |
Fixed assets | 84 84 |
Total Assets | 441 441 |
Jun '24 | |
Equity | 419 419 |
Debt capital | 22 22 |
Total Capital | 441 441 |
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Praxis Precision Medicines, Inc. is a clinical-stage genetic neuroscience company that develops therapies for patients and families affected by complex and debilitating brain disorders. The company was founded by Kiran Reddy, David Goldstein and Steven Petrou on September 22, 2015 and is headquartered in Cambridge, MA.
Head office | United States |
CEO | Marcio Souza |
Employees | 82 |
Founded | 2015 |
Website | www.praxismedicines.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.